INVA
Price:
$20.8
Market Cap:
$1.34B
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group...[Read more]
Industry
Biotechnology
IPO Date
2004-10-05
Stock Exchange
NASDAQ
Ticker
INVA
According to Innoviva, Inc.’s latest financial reports and current stock price. The company's current ROE is 5.68%. This represents a change of 370.28% compared to the average of 1.21% of the last 4 quarters.
The mean historical ROE of Innoviva, Inc. over the last ten years is 43.91%. The current 5.68% ROE has changed -87.06% with respect to the historical average. Over the past ten years (40 quarters), INVA's ROE was at its highest in in the December 2018 quarter at 171.74%. The ROE was at its lowest in in the September 2018 quarter at -42.29%.
Average
43.91%
Median
32.22%
Minimum
-55.23%
Maximum
257.23%
Discovering the peaks and valleys of Innoviva, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 227.49%
Maximum Annual ROE = 257.23%
Minimum Annual Increase = -565.70%
Minimum Annual ROE = -55.23%
| Year | ROE | Change |
|---|---|---|
| 2024 | 3.38% | -87.29% |
| 2023 | 26.63% | -29.58% |
| 2022 | 37.81% | -57.48% |
| 2021 | 88.93% | 113.97% |
| 2020 | 41.56% | -17.16% |
| 2019 | 50.17% | -80.49% |
| 2018 | 257.23% | -565.70% |
| 2017 | -55.23% | 227.49% |
| 2016 | -16.87% | -408.05% |
| 2015 | 5.48% | -92.74% |
The current ROE of Innoviva, Inc. (INVA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
22.61%
5-year avg
39.66%
10-year avg
43.91%
Innoviva, Inc.’s ROE is less than MiMedx Group, Inc. (19.18%), greater than Nektar Therapeutics (-356.81%), greater than Atai Beckley N.V (-107.86%), greater than Syndax Pharmaceuticals, Inc. (-160.60%), greater than Inhibrx Biosciences, Inc. (-186.06%), greater than Immatics N.V. (-23.26%), less than CureVac N.V. (29.18%), greater than Enliven Therapeutics, Inc. (-29.15%), greater than Relay Therapeutics, Inc. (-42.94%), greater than Dianthus Therapeutics, Inc. (-33.02%),
| Company | ROE | Market cap |
|---|---|---|
| 19.18% | $1.02B | |
| -356.81% | $1.17B | |
| -107.86% | $829.95M | |
| -160.60% | $1.71B | |
| -186.06% | $1.27B | |
| -23.26% | $1.44B | |
| 29.18% | $1.15B | |
| -29.15% | $1.27B | |
| -42.94% | $1.39B | |
| -33.02% | $1.62B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innoviva, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Innoviva, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Innoviva, Inc.'s ROE?
How is the ROE calculated for Innoviva, Inc. (INVA)?
What is the highest ROE for Innoviva, Inc. (INVA)?
What is the 3-year average ROE for Innoviva, Inc. (INVA)?
What is the 5-year average ROE for Innoviva, Inc. (INVA)?
How does the current ROE for Innoviva, Inc. (INVA) compare to its historical average?